Werewolf Therapeutics (HOWL) Competitors $1.77 -0.09 (-4.84%) (As of 12/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends HOWL vs. DSGN, KMDA, FATE, QTTB, SNDL, ACIU, VALN, ETON, ITOS, and PRQRShould you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include Design Therapeutics (DSGN), Kamada (KMDA), Fate Therapeutics (FATE), Q32 Bio (QTTB), SNDL (SNDL), AC Immune (ACIU), Valneva (VALN), Eton Pharmaceuticals (ETON), iTeos Therapeutics (ITOS), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry. Werewolf Therapeutics vs. Design Therapeutics Kamada Fate Therapeutics Q32 Bio SNDL AC Immune Valneva Eton Pharmaceuticals iTeos Therapeutics ProQR Therapeutics Werewolf Therapeutics (NASDAQ:HOWL) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends. Which has higher earnings and valuation, HOWL or DSGN? Werewolf Therapeutics has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWerewolf Therapeutics$19.94M4.03-$37.37M-$1.53-1.18Design TherapeuticsN/AN/A-$66.86M-$0.85-7.00 Is HOWL or DSGN more profitable? Design Therapeutics has a net margin of 0.00% compared to Werewolf Therapeutics' net margin of -578.80%. Design Therapeutics' return on equity of -18.01% beat Werewolf Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics-578.80% -58.83% -38.45% Design Therapeutics N/A -18.01%-17.38% Do insiders and institutionals hold more shares of HOWL or DSGN? 64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 21.1% of Werewolf Therapeutics shares are owned by company insiders. Comparatively, 31.2% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor HOWL or DSGN? Werewolf Therapeutics received 21 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 68.89% of users gave Werewolf Therapeutics an outperform vote while only 33.33% of users gave Design Therapeutics an outperform vote. CompanyUnderperformOutperformWerewolf TherapeuticsOutperform Votes3168.89% Underperform Votes1431.11% Design TherapeuticsOutperform Votes1033.33% Underperform Votes2066.67% Which has more volatility & risk, HOWL or DSGN? Werewolf Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500. Does the media prefer HOWL or DSGN? In the previous week, Werewolf Therapeutics had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 2 mentions for Werewolf Therapeutics and 1 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 1.89 beat Werewolf Therapeutics' score of 0.29 indicating that Design Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Werewolf Therapeutics Neutral Design Therapeutics Very Positive Do analysts rate HOWL or DSGN? Werewolf Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 564.82%. Design Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 17.65%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Design Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryWerewolf Therapeutics beats Design Therapeutics on 10 of the 17 factors compared between the two stocks. Ad Behind the MarketsHere’s how you could profit from the historic Trump rallyEx-Wall Street CEO crushed the market this year... Giving his readers a chance to outperform the S&P by as much as 164%. Now he's saying Trump's landslide win is opening up a rare window of opportunity.Click to get the name and ticker symbol Get Werewolf Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOWL vs. The Competition Export to ExcelMetricWerewolf TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$80.43M$6.70B$5.20B$9.09BDividend YieldN/A7.94%5.36%4.00%P/E Ratio-1.189.85129.4317.42Price / Sales4.03330.171,294.3081.84Price / CashN/A59.1741.8638.55Price / Book0.595.554.894.95Net Income-$37.37M$151.81M$118.58M$224.12M7 Day Performance-8.38%7.84%3.12%2.03%1 Month Performance-20.13%5.66%3.09%8.26%1 Year Performance-34.36%31.18%33.27%28.55% Werewolf Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOWLWerewolf Therapeutics3.1117 of 5 stars$1.77-4.8%$12.00+578.0%-27.1%$78.87M$19.94M-1.1640Short Interest ↑DSGNDesign Therapeutics1.0045 of 5 stars$6.05+0.8%$7.00+15.7%+138.6%$342.56MN/A-7.0140Positive NewsKMDAKamada3.912 of 5 stars$5.87-0.3%$14.50+147.0%+28.2%$337.41M$142.52M20.89360Short Interest ↑FATEFate Therapeutics4.28 of 5 stars$2.91-8.2%$6.75+132.0%-0.8%$331.42M$63.53M-1.75550QTTBQ32 Bio3.2523 of 5 stars$26.51-1.5%$72.33+172.9%N/A$322.92M$-6,651,000.00-1.9639SNDLSNDL3.5733 of 5 stars$1.94+0.3%$3.25+68.0%+27.3%$321.25M$911.22M-6.232,516ACIUAC Immune2.2726 of 5 stars$3.22-5.3%$12.00+272.7%-5.6%$318.59M$16.48M-6.91140Positive NewsVALNValneva2.6089 of 5 stars$3.91-3.5%$18.50+373.1%-66.2%$317.68M$158.54M-29.62700News CoverageGap UpHigh Trading VolumeETONEton Pharmaceuticals2.1126 of 5 stars$12.22-9.7%$15.00+22.7%+219.5%$315.77M$31.64M-57.1420Short Interest ↑Gap UpHigh Trading VolumeITOSiTeos Therapeutics3.6996 of 5 stars$8.53-0.2%$31.50+269.3%-15.8%$311.64M$35M-2.7190Positive NewsPRQRProQR Therapeutics2.8976 of 5 stars$3.79-1.3%$7.13+88.0%+112.1%$309.57M$17.88M-12.00180 Related Companies and Tools Related Companies Design Therapeutics Alternatives Kamada Alternatives Fate Therapeutics Alternatives Q32 Bio Alternatives SNDL Alternatives AC Immune Alternatives Valneva Alternatives Eton Pharmaceuticals Alternatives iTeos Therapeutics Alternatives ProQR Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HOWL) was last updated on 12/4/2024 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredLock in this share price before 12/5When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying atten...Pacaso | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredStrange: Why is Amazon suddenly yielding 39.70%?Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A...Investors Alley | SponsoredThis frightening chart explains everything going on in the economy (see photo)Why the wealth gap is getting wider — with the one percenters growing ever richer and ever more powerful, whil...Banyan Hill Publishing | SponsoredExpert: The most important message you’ll see in 2024The message I'm sharing today could be the most important message of 2024. In short, America is being invad...InvestorPlace | SponsoredMeet the NYSE traded company behind a potentially blockbuster antiviral drugThis public company’s one lead drug alone, NV-387, potentially addresses a $2.5 to $4.3 billion market Imag...Smallcaps Daily | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HOWL Stock Alerts